Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $91,542 | $25,976 |
| Restricted cash | 7,565 | 9,251 |
| Trade accounts receivable, net | 613,732 | 741,791 |
| Inventories | 581,384 | 530,735 |
| Prepaid expenses and other current assets | 82,685 | 103,565 |
| Related party receivables | 955 | 500 |
| Total current assets | 1,377,863 | 1,411,818 |
| Property, plant and equipment, net | 447,574 | 469,815 |
| Goodwill | 598,629 | 598,853 |
| Intangible assets, net | 890,423 | 1,096,093 |
| Operating lease right-of-use assets | 30,329 | 38,211 |
| Operating lease right-of-use assets - related party | 12,954 | 17,910 |
| Financing lease right-of-use assets | 59,280 | 63,424 |
| Other assets | 55,517 | 103,217 |
| Total assets | $3,472,569 | $3,799,341 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $534,662 | $538,199 |
| Current portion of liabilities for legal matters | 76,988 | 107,483 |
| Revolving credit facility | 179,000 | 60,000 |
| Current portion of long-term debt, net | 34,125 | 29,961 |
| Current portion of operating lease liabilities | 9,207 | 8,321 |
| Current portion of operating lease liabilities - related party | 2,825 | 2,869 |
| Current portion of financing lease liabilities | 2,467 | 3,488 |
| Related party payables - short term | 7,321 | 2,479 |
| Total current liabilities | 846,595 | 752,800 |
| Long-term debt, net | 2,386,004 | 2,591,981 |
| Note payable - related party | 41,447 | 39,706 |
| Operating lease liabilities | 24,095 | 32,126 |
| Operating lease liabilities - related party | 12,787 | 15,914 |
| Financing lease liabilities | 58,566 | 60,769 |
| Related party payable - long term | 11,776 | 9,649 |
| Other long-term liabilities | 29,995 | 87,468 |
| Total long-term liabilities | 2,564,670 | 2,837,613 |
| Commitments and contingencies (Notes 5 and 21) | ||
| Redeemable non-controlling interests | 41,293 | 24,949 |
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both December 31, 2023 and 2022 | — | — |
| Class A common stock, $0.01 par value, 900,000 shares authorized at both December 31, 2023 and 2022; 306,565 and 151,490 shares issued at December 31, 2023 and 2022, respectively | 3,066 | 1,514 |
| Class B common stock, $0.01 par value, 300,000 shares authorized at December 31, 2023 and 2022; 152,117 shares issued at December 31, 2022; None issued at December 31, 2023 | — | 1,522 |
| Additional paid-in capital | 539,240 | 691,629 |
| Stockholders' accumulated deficit | (490,176) | (406,183) |
| Accumulated other comprehensive (loss) income | (32,349) | 9,939 |
| Total Amneal Pharmaceuticals, Inc. stockholders' equity | 19,781 | 298,421 |
| Non-controlling interests | 230 | (114,442) |
| Total stockholders' equity | 20,011 | 183,979 |
| Total liabilities and stockholders' equity | $3,472,569 | $3,799,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.